Biotech News
Related news
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURAZura Bio2026-08-11 11:30 EST
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
CUECue Biopharma Inc2026-08-03 12:30 EST
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
BNTXBioNTech2026-08-03 09:00 EST
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
VERAVera Therapeutics2026-07-09 12:00 EST
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
KYTXKyverna Therapeutics2026-06-22 12:00 EST
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
TLSATiziana Life Sciences2026-08-06 11:00 EST
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
CUECue Biopharma Inc2026-07-13 12:30 EST
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
XFORX4 Pharmaceuticals2026-07-01 11:00 EST
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
SABSSAB Biotherapeutics2026-08-06 11:30 EST
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Zura Bio
Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...
Recent company news
ZURAZura Bio2026-08-11 11:30 EST
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURAZura Bio2026-05-14 11:30 EST
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-05-13 11:30 EST
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
ZURAZura Bio2026-05-07 11:30 EST
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Stock data
- Close
- 5.68 USD
- Market cap
- 389.01M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States